Several companies have adjusted their earnings-per-share forecasts for the year from what they had issued when they announced fourth-quarter 2019 earnings or expect to see negative impacts on sales of certain drug products, while others reaffirmed guidances.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,